INT J LAB HEMATOL:新型网状红细胞和红细胞参数在Sysmex xn9000治疗孕妇铁缺乏中的临床应用

2019-02-01 MedSci MedSci原创

缺铁(ID)是妊娠期发病的主要原因。目前,产前诊所使用血红蛋白对ID进行筛查,但会延误亚临床ID的诊断。本研究旨在探讨怀孕患者Sysmex的血液学分析仪测定的微细胞红细胞百分比 (%微观检测R),低红细胞百分比(%海波他应承担的)和网织红细胞血红蛋白含量((Ret‐He) 的临床应用价值。 本研究对102例首次到产前门诊就诊的妊娠前三个月非贫血患者进行ID筛查,根据研究定义,其中50例(4

缺铁(ID)是妊娠期发病的主要原因。目前,产前诊所使用血红蛋白对ID进行筛查,但会延误亚临床ID诊断。本研究旨在探讨怀孕患者Sysmex血液学分析仪测定的微细胞红细胞百分比 (%微观检测R),低红细胞百分比(%海波他应承担的)和网织红细胞血红蛋白含量((RetHe) 临床应用价值。

本研究对102例首次到产前门诊就诊的妊娠前三个月非贫血患者进行ID筛查,根据研究定义,其中50(49.02%)ID。采用独立t检验和接受者工作曲线(ROC)分析。

结果显示,ID组和非IDRet - He%Micro - R%Hypo - He存在显著差异(P < 0.001)RetHe (0.81, 95% CI 0.710.88)的曲线下面积(AUC)表明,在小于31.2 pg的截止时间,RetHeID的最佳鉴别 (P < 0.0001)%HypoHe (0.78, 95% CI 0.690.86)AUC并不优于平均细胞血红蛋白(0.78,95% CI 0.690.86)。与平均细胞体积(0.75,95% CI 0.650.83)相比,%MicroR (0.79, 95% CI 0.700.87)显示出更高的诊断准确性。

研究表明,新的网状红细胞和红细胞参数是诊断妊娠期亚临床ID的可靠指标。然而,还需要进一步的研究来证实红细胞参数对孕妇的诊断价值。这些检测将有助于对产前诊所的孕妇的有效管理

原始出处:

Shani Levy Elise Schapkaitz The clinical utility of new reticulocyte and erythrocyte parameters on the Sysmex XN 9000 for iron deficiency in pregnant patients

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1835790, encodeId=11121835e90e4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Jun 23 13:30:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282025, encodeId=8024128202552, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317476, encodeId=26f4131e476f3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392110, encodeId=f5f6139211064, content=<a href='/topic/show?id=99ae9655694' target=_blank style='color:#2F92EE;'>#铁缺乏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96556, encryptionId=99ae9655694, topicName=铁缺乏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1835790, encodeId=11121835e90e4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Jun 23 13:30:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282025, encodeId=8024128202552, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317476, encodeId=26f4131e476f3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392110, encodeId=f5f6139211064, content=<a href='/topic/show?id=99ae9655694' target=_blank style='color:#2F92EE;'>#铁缺乏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96556, encryptionId=99ae9655694, topicName=铁缺乏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-02-03 kord1982
  3. [GetPortalCommentsPageByObjectIdResponse(id=1835790, encodeId=11121835e90e4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Jun 23 13:30:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282025, encodeId=8024128202552, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317476, encodeId=26f4131e476f3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392110, encodeId=f5f6139211064, content=<a href='/topic/show?id=99ae9655694' target=_blank style='color:#2F92EE;'>#铁缺乏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96556, encryptionId=99ae9655694, topicName=铁缺乏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-02-03 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=1835790, encodeId=11121835e90e4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Jun 23 13:30:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282025, encodeId=8024128202552, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317476, encodeId=26f4131e476f3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392110, encodeId=f5f6139211064, content=<a href='/topic/show?id=99ae9655694' target=_blank style='color:#2F92EE;'>#铁缺乏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96556, encryptionId=99ae9655694, topicName=铁缺乏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Feb 03 02:30:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]

相关资讯

Anal. Chem:微生物所在微滴数字PCR技术研制方面取得进展

数字PCR是一种用于绝对核酸定量检测方法,具有前所未有的准确度和精确度,是继实时荧光定量PCR技术之后的第三代核酸定量扩增检测技术,在液体活检、肿瘤伴随诊断、无创产前筛查、病原载量监测等方面具有重要应用前景,是科研和临床领域的平台级新技术。数字PCR市场主流产品主要为欧美跨国公司的高端仪器,在科研和临床的应用还比较初步。数字PCR的更广泛使用和临床应用,仍然存在几个主要挑战,包括降低成本,集成仪器

临床应用碳青霉烯类抗菌药物,这些内容要清楚!(附详细用药剂量)

近年来,我国碳青霉烯类抗菌药物在临床应用中出现了一些不合理现象,部分细菌对其耐药性呈明显上升趋势。中华人民共和国卫生与健康委员会组织相关领域专家多次研究论证,形成《碳青霉烯类抗菌药物临床应用专家共识》。对碳青霉烯类抗菌药物临床应用提出了专家建议。

中国成人多导睡眠监测技术操作规范及临床应用专家共识

随着现代医学对睡眠疾病的认识逐渐提高,睡眠监测技术得到越来越广泛的应用,在神经科、呼吸科、耳鼻咽喉科、口腔科、精神科等临床科室均有开展。 作为睡眠医学临床和科研的重要工具,多导睡眠监测技术的价值日益受到重视,为进一步明确我国多导睡眠监测技术临床适应证范围,规范操作流程,统一诊断术语和报告形式,中国医师协会神经内科医师分会睡眠障碍专业委员会发起并同中国睡眠研究会睡眠障碍专业委员会和中华医学会神经病学

IEEE Trans Med Imaging:中国科大在医学电阻抗成像领域取得新进展

近日,中国科学院院士、中国科学技术大学教授杜江峰领导的中科院微观磁共振重点实验室在医学电阻抗成像领域取得新进展。该团队开发出一种精准、高效且稳定的动态医学电阻抗图像重构方法,成功获得了动物血胸、气胸状态下高分辨电阻抗图像。相关研究成果以A Parametric Level Set based Approach to Difference Imaging in Electrical Impedanc

DPP-4抑制剂临床应用专家共识

传统降糖药物在糖尿病的治疗中发挥着巨大的作用,但是由于糖尿病发病机制的复杂性,传统降糖药物仍然不能满足临床需要。因此,开发具有新作用机制的抗糖尿病药物具有十分重要的意义。 近年涌现出一些与传统降糖药物作用机制迥异的新药,二肽基肽酶-4 (DPP-4)抑制剂即是其中之一、目前已问世的 DPP-4抑制剂有几十种 ,国内上市的有西格列汀、维格列汀、沙格列汀、阿格列汀和利格列汀、 这些药物被统称为格列汀(

外泌体研究、转化和临床应用专家共识

由于外泌体在肿瘤等疾病的基础研究、转化应用和诊断治疗中展现出的巨大潜力而备受瞩目。在发展精准医疗产业的背景下,如何建立相关领域的标准与规范,促进产学研结合,理性引导技术转化,需要来自于基础科研、临床、检验等领域的专家,以及监管部门的多方参与合作。为推动和促进国内外泌体特别是外泌体肿瘤标志物的研究和转化应用的有序开展,中国抗癌协会肿瘤标志专业委员会外泌体技术专家委员会组织专家撰写了外泌体研究、转化和